Firstly, the survival of EGFR+ NSCLC patients has been significantly prolonged.6 Secondly, first (i.e. gefitinib) and second‐generation (afatinib) EGFR‐TKIs have poor penetration across the blood–brain barrier (BBB). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.